Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
Class Amines; Antineoplastics; Cardiovascular therapies; Chlorobenzenes; Imidazoles; Ketones; Quinolines; Small molecules
Mechanism of Action Farnesyltranstransferase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma; T-cell lymphoma; Acute myeloid leukaemia
New Molecular Entity Yes

Phase III Acute myeloid leukaemia; Pancreatic cancer
Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
Phase I/II Multiple myeloma
Preclinical Renal cell carcinoma
No development reported Cutaneous T-cell lymphoma; Hypertrophic cardiomyopathy; Rhabdomyosarcoma; Solid tumours
Discontinued Breast cancer; Glioblastoma

28 Dec 2025 No recent reports of development identified for preclinical development in Hypertrophic-cardiomyopathy in USA
06 Dec 2025 Pharmacodynamics data from a clinical data from clinical studies presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)
18 Oct 2025 Efficacy and adverse events data from a phase I/II KURRENT-HN trial in Squamous cell cancer released by Kura Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com